Kidney Transplant
Conditions
Keywords
kidney transplant, Tacrolimus, Prograf, Advagraf, FK506
Brief summary
The purpose of this study is to confirm non-inferiority of delayed Prograf treatment to standard Prograf treatment in the incidence of delayed graft function (DGF) within 1 week between the 2 immunosuppressive (IS) treatment groups: delayed or standard Prograf together with induction therapy, and then convert to Advagraf usage in donation after cardiac (or circulatory) death (DCD) kidney transplant recipients. This study will also compare the clinical outcome within 6 month post-transplant between the 2 IS treatment groups and compare the safety throughout study period between the 2 IS treatment groups.
Interventions
DRUGTacrolimus immediate-release formulation
oral
DRUGTacrolimus prolonged-release formulation
oral
All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
DRUGMycophenolic acid drugs
All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
DRUGCorticosteroids
All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
Sponsors
Astellas Pharma China, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Subject has end-stage kidney disease who is a suitable candidate for primary DCD kidney transplantation. * Subject is a resident of China. * Subject is scheduled to undergo DCD renal allograft transplantation with compatible ABO blood type. * Subject has peak panel-reactive antibodies (PRA) \< 10% or Negative test result. * Subject must be a recipient of a DCD kidney and receive the organ distributed by China Organ Transplant Response System only. * Female subject must either: * Be of non-childbearing potential: Postmenopausal (defined as at least 1 year without any menses for which there is no other obvious pathological or physiological cause) prior to screening, or documented surgically sterile * Or, if of childbearing potential: Agree not to try to become pregnant throughout the study period and have a negative blood pregnancy test at screening. * A sexually active male or female subject is utilizing highly effective forms of birth control starting at screening and throughout the study period if the risk of conception exists. * Subject agrees not to participate in another interventional study while participating in the present study from 1 month before randomization to 1 month after the last dose of investigational drug.
Exclusion criteria
* Subject has previously received or is receiving an organ transplant other than kidney. * Subject is receiving double-kidney transplant. * Recipients of Maastricht Class I, II, and V donor organs. * Recipients of Maastricht Class III and IV donor organs without a full complement of intensive care unit and intraoperative records. * Subject has cold ischemia time of allograft \> 24 hours before kidney transplantation surgery. * Subject has known contraindication to administration of tacrolimus (Prograf or Advagraf), or other macrolides. * Subject is unlikely to comply with the visits scheduled in the protocol or has a history of non-compliance. * Subject has evidence of active liver disease or the presence of a chronic active hepatitis B or C within 1 month prior to kidney transplant surgery. * Recipient or donor is seropositive for human immunodeficiency virus. * Subject has active systemic infection requiring the use of antimicrobial agents within 1 week prior to kidney transplant surgery. * Subject has current malignancy or a history of malignancy (within the past 5 years), except non- metastatic basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix that has been treated successfully. * Subject has medical or psychological conditions which would preclude compliance with the study requirements. * Subject has any condition, including any uncontrolled disease state other than end-stage kidney disease, that constitutes an inappropriate risk or a contraindication for participation in the study, or that could interfere with the study objectives, conduction, or evaluation. * Female subject who breastfeed or donate ova starting at screening and throughout the study period. * Male subject who donate sperm starting at screening and throughout the study period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of delayed graft function (DGF) | Up to Day 7 after transplantation | DGF is defined as dialysis requirement during the first post-transplant week (7 days). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of acute rejection (AR) | Up to Month 6 after transplantation | The reporting of AR includes any biopsy-proven or clinically-suspected rejection of a subject after transplantation. |
| Renal function assessed by estimated glomerular filtration rate (eGFR) | Up to Month 6 after transplantation | eGFR will be derived using the abbreviated Modification of Diet in Renal Disease (MDRD) formula. |
| Renal function assessed by serum creatinine | Up to Month 6 after transplantation | Serum creatinine will be measured from serum sample collected. |
| Renal function assessed by urea nitrogen | Up to Month 6 after transplantation | Urea nitrogen will be measured from serum sample collected. |
| Subject survival | Up to Month 6 after transplantation | Subject survival is the time from the date of transplantation to the date of death or the date of the last follow-up. Subject survival will be estimated using Kaplan Meier estimates and compared by log rank test. |
| Number of participants with laboratory test abnormalities and/or AEs | Up to Month 7 after transplantation | Number of participants with potentially clinically significant laboratory values. |
| Safety assessed by incidence of treatment-emergent adverse events (TEAEs) | Up to Month 7 after transplantation | Adverse events (AEs) will be coded using the latest version of MedDRA. TEAE is defined as any AE following the transplantation until the end of the study. |
| Safety assessed by incidence of serious adverse events (SAEs) | Up to Month 7 after transplantation | AE is considered serious if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event. |
| Number of participants with vital sign abnormalities and/or AEs | Up to Month 7 after transplantation | Number of participants with potentially clinically significant vital sign values. |
| Number of participants with 12-lead electrocardiograms (ECG) abnormalities and/or AEs | Up to Month 7 after transplantation | ECG will be performed in the supine position after the subject has been breathing quietly for 5 minutes. Any clinically significant adverse changes on the ECG will be reported as AEs. |
| Graft survival | Up to Month 6 after transplantation | Graft survival is an estimate of the probability of the transplant functioning at a finite time after transplantation. Graft survival will be calculated from the date of transplantation to the date of irreversible graft failure or the date of the last follow-up during the period when the transplant is still functioning or to the date of death. |
Countries
China
Outcome results
None listed